
Bioventus (BVS) Stock Forecast & Price Target
Bioventus (BVS) Analyst Ratings
Bulls say
Bioventus Inc. reported a total revenue of $55.5 million in its surgical solutions segment, reflecting a 3.4% increase as reported and a 10.3% growth excluding divestiture impacts, primarily driven by effective commercial strategies and strong sales execution. The pain treatments segment showcased impressive performance with revenues of $79.7 million, and anticipated investments are expected to yield further growth in the latter half of 2026 and beyond. Management projects a low-double-digit percentage growth for the surgical solutions business in 2026 and foresees significant improvement in adjusted EBITDA margins by 200 to 250 basis points between 2025 and 2030, suggesting a positive long-term outlook for the company.
Bears say
Bioventus Inc. is facing a negative outlook due to anticipated elevated investment levels in key growth areas while simultaneously experiencing flat to declining adjusted EBITDA margins for 2026 and 2027 compared to 2025. The company reported a significant decline of 26.0% in restorative therapies revenue, reflecting ongoing challenges in both domestic and international markets, alongside an overall revenue growth of only 5.3%. Additionally, the gross margin decreased to 68.9%, falling short of estimates, which further illustrates the financial pressures impacting Bioventus's profitability.
This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.
Bioventus (BVS) Analyst Forecast & Price Prediction
Start investing in Bioventus (BVS)
Order type
Buy in
Order amount
Est. shares
0 shares